UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event Reported): February 28, 2024
Amphastar Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
laware | 001-36509 | 33-0702205 |
(State or Other Jurisdiction of | (Commission File Number) | (I.R.S. Employer Identification |
11570 6th Street | |
Rancho Cucamonga, California | 91730 |
(Address of Principal Executive Offices) | (Zip Code) |
Registrant's telephone number, including area code: (909) 980-9484
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||
Common Stock, par value $0.0001 per share | AMPH | The NASDAQ Stock Market LLC | ||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On February 28, 2024, Amphastar Pharmaceuticals, Inc. issued a press release announcing its financial results for the three months and fiscal year ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
Exhibit No. |
| Description |
99.1 | Press release, dated February 28, 2024, issued by Amphastar Pharmaceuticals, Inc. | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 28, 2024 | Amphastar Pharmaceuticals, Inc. | ||
By: | /s/ WILLIAM J. PETERS | ||
William J. Peters | |||
Chief Financial Officer, Executive Vice President and Treasurer | |||
EXHIBIT 99.1
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2023
Reports Net Revenues of $178.1 Million for the Three Months Ended December 31, 2023
RANCHO CUCAMONGA, CA – February 28, 2024 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months and full-year ended December 31, 2023.
Fourth Quarter Highlights
| ● | Net revenues of $178.1 million for the fourth quarter |
| ● | GAAP net income of $36.2 million, or $0.68 per share, for the fourth quarter |
| ● | Adjusted non-GAAP net income of $46.9 million, or $0.88 per share, for the fourth quarter |
Full-Year Highlights
| ● | Net revenues of $644.4 million for the fiscal year |
| ● | GAAP net income of $137.5 million, or $2.60 per share, for the fiscal year |
| ● | Adjusted non-GAAP net income of $175.7 million, or $3.32 per share, for the fiscal year |
Dr. Jack Zhang, Amphastar’s President and Chief Executive Officer, commented: “We enter 2024 with strong momentum. 2023 was an important year for the Company driven by the strong performance of glucagon and Primatene MIST® alongside the acquisition of BAQSIMI®, which strengthened our diabetes portfolio. The recent submission of our first BLA for Insulin Aspart, known as AMP-004, underscores our continued pipeline development in diabetes management, and marks another milestone for Amphastar.”
* Adjusted non-GAAP net income and adjusted non-GAAP diluted EPS are non-GAAP financial measures. Please see the discussion in the section entitled “Non-GAAP Financial Measures” and the reconciliation of GAAP to non-GAAP financial measures in Table III of this press release.
Fourth Quarter Results
| | Three Months Ended | | | | | | | ||||
| | December 31, | | Change | | |||||||
| | 2023 | | 2022 | | Dollars |
| % | | |||
| | (in thousands) | | | | |||||||
Product revenues: |
| |
|
| |
| | | | | | |
Glucagon | | $ | 31,198 | | $ | 18,319 | | $ | 12,879 | | 70 | % |
Epinephrine | | | 24,646 | | | 21,427 | | | 3,219 | | 15 | % |
Primatene MIST® | | | 24,484 | | | 22,279 | | | 2,205 | | 10 | % |
Lidocaine | | | 14,988 | | | 13,286 | | | 1,702 | | 13 | % |
Phytonadione | | | 11,922 | | | 11,666 | | | 256 | | 2 | % |
Enoxaparin | | | 6,092 | | | 7,812 | | | (1,720) | | (22) | % |
Naloxone | | | 4,230 | | | 4,845 | | | (615) | | (13) | % |
Other finished pharmaceutical products | |
| 35,015 | |
| 33,082 | |
| 1,933 |
| 6 | % |
Total finished pharmaceutical products net revenues | | $ | 152,575 | | $ | 132,716 | | $ | 19,859 |
| 15 | % |
API | | | 3,074 | | | 2,307 | | | 767 | | 33 | % |
Other revenues | | | 22,456 | | | — | | | 22,456 | | N/A | |
Total product revenues, net | | $ | 178,105 | | $ | 135,023 | | $ | 43,082 | | 32 | % |
Changes in product revenues as compared to the fourth quarter of the prior year were primarily driven by:
| ● | Glucagon sales increased primarily due to an increase in unit volumes, as a result of two competitors discontinuing their glucagon injection products at the end of 2022 |
| ● | Epinephrine sales increased primarily due to an increase in unit volumes, as a result of supplier shortages |
| ● | Lidocaine sales increased primarily due to higher unit volumes as supply chain issues eased allowing us to fulfill backorders |
| ● | Primatene MIST® sales increased $1.3 million due to an increase in unit volumes, with the remainder of the increase due to an increase in average selling price |
| ● | Enoxaparin and naloxone sales decreased primarily due to a decrease in unit volumes |
| ● | Other finished pharmaceutical product sales increased primarily due to: |
| o | Higher unit volumes of atropine, calcium chloride, and sodium bicarbonate, due to increased demand caused by supplier shortages during the fourth quarter |
| o | Launch of regadenoson in April 2023 |
| ● | Active Pharmaceutical Ingredient (“API”) sales increased primarily due to the timing of customer purchases |
Other revenues are comprised of net revenues from the sales of BAQSIMI® of $22.5 million during the three months ended December 31, 2023, which was recognized on a net basis similar to a royalty arrangement and based on Eli Lilly & Company’s (“Lilly”) reported BAQSIMI® net sales of $37.6 million. Currently, BAQSIMI® is being sold by Lilly on our behalf under the Transition Services Agreement (“TSA”) with Lilly, whereby Lilly provides certain services to support the transition of the BAQSIMI® operations to us. Once Amphastar takes over the distribution of BAQSIMI®, Amphastar will recognize the entire revenue amount. This revenue recognition change is expected to be phased in by country during 2024.
Changes in the cost of revenues and gross margin were primarily driven by:
| ● | Increased sales of higher-margin products such as glucagon and Primatene MIST®, as well as the sales of |
| regadenoson, which we launched in April 2023. |
| ● | As a result of the TSA, the revenue relating to BAQSIMI® is recognized on a net basis within net revenues. |
| ● | These factors were partially offset by charges included in cost of revenues to adjust our inventory and related purchase commitments to their net realizable value, which includes a $3.6 million inventory reserve as a result of amending the Supply Agreement with MannKind Corporation in December 2023. |
| ● | Selling, distribution, and marketing expenses increased primarily due to expenses related to the expansion of our sales and marketing efforts related to BAQSIMI®. |
| ● | General and administrative expenses increased primarily due to an increase in salary and personnel-related expenses, as well as costs related to the acquisition of BAQSIMI®, which was partially offset by a decrease in legal fees. |
| ● | Research and development expenses increased due to an increase in materials and supply expenses, primarily related to our inhalation pipeline products. |
| ● | The change in non-operating (expenses) income, net is primarily a result of: |
| ◾ | Interest expense in the fourth quarter of 2023, which was primarily related to our Wells Fargo Bank syndicated loan, as well as our convertible debt |
| ◾ | Foreign currency fluctuations |
| ◾ | Mark-to-market adjustments relating to our interest rate swap contracts. |
Year-End Results
| | Year Ended December 31, | | Change | | |||||||
| | 2023 | | 2022 | | Dollars |
| % | | |||
| | (in thousands) | | | | |||||||
Product revenues: |
| |
|
| |
| | | | | | |
Glucagon | | $ | 113,684 | | $ | 55,322 | | $ | 58,362 | | 105 | % |
Primatene MIST® | | | 89,321 | | | 84,309 | | | 5,012 | | 6 | % |
Epinephrine | | | 81,650 | | | 74,204 | | | 7,446 | | 10 | % |
Lidocaine | | | 58,162 | | | 52,539 | | | 5,623 | | 11 | % |
Phytonadione | |
| 44,939 | |
| 49,500 | | | (4,561) | | (9) | % |
Enoxaparin | | | 31,533 | | | 34,950 | | | (3,417) | | (10) | % |
Naloxone | | | 19,004 | | | 26,269 | | | (7,265) | | (28) | % |
Other finished pharmaceutical products | |
| 140,823 | |
| 109,412 | |
| 31,411 |
| 29 | % |
Total finished pharmaceutical products net revenues | | $ | 579,116 | | $ | 486,505 | | $ | 92,611 |
| 19 | % |
API | | | 14,122 | | | 12,482 | | | 1,640 | | 13 | % |
Other revenues | | | 51,157 | | | — | | | 51,157 | | N/A | |
Total product revenues, net | | $ | 644,395 | | $ | 498,987 | | $ | 145,408 | | 29 | % |
Changes in product revenues were primarily driven by:
| ● | Glucagon sales increased primarily due to an increase in unit volumes as a result of two competitors discontinuing their glucagon injection products at the end of 2022 |
| ● | Primatene MIST® sales increased due to an increase in the average selling price |
| ● | Epinephrine and lidocaine sales increased primarily due to an increase in unit volumes as a result of supplier shortages |
| ● | Phytonadione sales decreased due to lower unit volumes as a result of increased competition |
| ● | Enoxaparin sales decreased primarily due to a decrease in unit volumes |
| ● | Sales of naloxone decreased due to lower unit volumes, reducing sales by $4.6 million, as well as a lower average selling price, reducing sales by $2.7 million as a result of increased competition |
| ● | Other finished pharmaceutical product sales increased primarily due to: |
| o | Higher unit volumes of dextrose, atropine, calcium chloride, and sodium bicarbonate due to increased demand caused by supplier shortages during the year |
| o | A full year of sales for ganirelix and vasopressin, which was launched in June 2022 and August 2022, respectively |
| o | Launch of regadenoson in April 2023 |
| ● | API sales increased primarily due to the timing of customer purchases |
Other revenues are comprised of net revenues from the sales of BAQSIMI® of $51.2 million during the year ended December 31, 2023, which was recognized on a net basis similar to a royalty and based on Lilly’s reported BAQSIMI® net sales of $86.3 million.
Changes in the cost of revenues and gross margin were primarily driven by:
| ● | Increased sales of higher-margin products such as glucagon and Primatene MIST®, the sales of ganirelix and vasopressin that were launched in 2022, as well as the sales of regadenoson, which we launched in April 2023 |
| ● | As a result of the TSA, the revenue relating to BAQSIMI® is recognized on a net basis within net revenues. |
| ● | These factors were partially offset by an impairment charge of $2.7 million related to the impairment of the IMS (UK) international product rights, as well as charges included in cost of revenues to adjust our inventory and related purchase commitments to their net realizable value, which includes a $3.6 million inventory reserve as a result of amending the Supply Agreement with MannKind Corporation in December 2023 |
| ● | Selling, distribution, and marketing expenses increased primarily due to expenses related to the expansion of our sales and marketing efforts related to BAQSIMI®, as well as an increase in advertising spending for Primatene MIST® |
| ● | General and administrative expenses increased primarily due to an increase in salary and personnel-related expenses, as well as costs related to the acquisition of BAQSIMI®, which was partially offset by a decrease in legal fees |
| ● | Research and development expenses decreased due to: |
| ◾ | Decreases in materials and supply expenses as a result of a ramp-up of expenses in 2022 for AMP-018 and our insulin pipeline products |
| ◾ | This decrease was partially offset by an increase in salary and personnel-related expenses |
| ● | The change in non-operating (expenses) income, net is primarily a result of: |
| ◾ | Foreign currency fluctuations |
| ◾ | Costs incurred in connection with the syndicated credit agreement we entered into with Wells Fargo Bank, as syndication agent, to finance the acquisition of BAQSIMI® |
| ◾ | Mark-to-market adjustments relating to our interest rate swap contracts |
Cash flow provided by operating activities for the year ended December 31, 2023 was $183.5 million.
Pipeline Information
The Company currently has four abbreviated new drug applications (“ANDAs”) and one biosimilar insulin candidate on file with the U.S. Food and Drug Administration (the “FDA”) targeting products with a market size of over $3 billion and $4 billion, respectively, three biosimilar products in development targeting products with a market size of over $10 billion, and six generic products in development targeting products with a market size of over $8 billion. This market information is based on IQVIA data for the 12 months ended December 31, 2023. The Company is developing multiple proprietary products with injectable and intranasal dosage forms.
Amphastar’s Chinese subsidiary, Amphastar Nanjing Pharmaceuticals, Co., Ltd. (“ANP”), currently has multiple Drug Master Files (“DMFs”), on file with the FDA and is developing several additional DMFs.
Company Information
Amphastar is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin API products. Most of the Company’s finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information and resources are available at www.amphastar.com.
Amphastar’s logo and other trademarks or service marks of Amphastar, including, but not limited to Amphastar®, BAQSIMI®, Primatene MIST®, REXTOVYTM, Amphadase®, and Cortrosyn®, are the property of Amphastar.
Non-GAAP Financial Measures
To supplement its consolidated financial statements, which are prepared and presented in accordance with U.S. generally accepted accounting principles (“GAAP”), the Company is disclosing non-GAAP financial measures when providing financial results. The Company believes that an evaluation of its ongoing operations (and comparisons of its current operations with historical and future operations) would be difficult if the disclosure of its financial results were limited to financial measures prepared only in accordance with GAAP. As a result, the Company is disclosing certain non-GAAP results, including (i) Adjusted non-GAAP net income (loss) and (ii) Adjusted non-GAAP diluted EPS, which exclude amortization expense, share-based compensation, impairment charges, expenses related to our acquisition of BAQSIMI®, debt issuance costs, legal settlements, and other one-time events in order to supplement investors’ and other readers’ understanding and assessment of the Company’s financial performance because the Company’s management uses these measures internally for forecasting, budgeting, and measuring its operating performance. Whenever the Company uses such non-GAAP measures, it will provide a reconciliation of non-GAAP financial measures to their most directly comparable GAAP financial measures. Investors and other readers are encouraged to review the related GAAP financial measures and the reconciliation of non-GAAP measures to their most directly comparable GAAP measures set forth below and should consider non-GAAP measures only as a supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with GAAP.
Conference Call Information
The Company will hold a conference call to discuss its financial results today, February 28, 2024, at 2:00 p.m. Pacific Time.
To access the conference call, dial toll-free (877) 407-0989 or (201) 389-0921 for international callers, ten minutes before the conference.
The call can also be accessed on the Investors page on the Company’s website at www.amphastar.com.
Forward-Looking Statements
All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth, sales and marketing of our products, market size and expansion, product
portfolio, product development, the timing of FDA filings or approvals, including the DMFs of ANP, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the prospective benefits of the acquisition of BAQSIMI®, and other future events. These statements are not facts but rather are based on Amphastar’s historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as “may,” “might,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar’s control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar’s filings with the Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 1, 2023, in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, filed with the SEC on May 9, 2023, in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, filed with the SEC on August 8, 2023, and in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, filed with the SEC on November 8, 2023. In particular, there can be no guarantee that the acquisition of BAQSIMI® will be beneficial to our business, that any event, change or other circumstance could cause the results of the acquisition and integration of BAQSIMI® into our product portfolio to differ from Amphastar’s expectation, that all or any of the contingent consideration will be payable on the terms described herein or at all, or that Amphastar can reliably predict the impact of BAQSIMI® on its financial results or financial guidance. You can locate these reports through our website at http://ir.amphastar.com and on the SEC’s website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.
Contact Information:
Amphastar Pharmaceuticals, Inc.
Bill Peters
Chief Financial Officer
(909) 476-3416
Table I
Amphastar Pharmaceuticals, Inc.
Condensed Consolidated Statement of Operations
(Unaudited; in thousands, except per share data)
Table II
Amphastar Pharmaceuticals, Inc.
Condensed Consolidated Balance Sheets
(Unaudited; in thousands, except share data)
|
| December 31, |
| December 31, | ||
| | 2023 | | 2022 | ||
ASSETS | | | | | | |
Current assets: | | | | | | |
Cash and cash equivalents | | $ | 144,296 | | $ | 156,098 |
Restricted cash | | | 235 | | | 235 |
Short-term investments | | | 112,510 | | | 19,664 |
Restricted short-term investments | |
| 2,200 | |
| 2,200 |
Accounts receivable, net | |
| 114,943 | |
| 88,804 |
Inventories | |
| 105,833 | |
| 103,584 |
Income tax refunds and deposits | |
| 526 | |
| 171 |
Prepaid expenses and other assets | |
| 9,057 | |
| 7,563 |
Total current assets | |
| 489,600 | |
| 378,319 |
| | | | | | |
Property, plant, and equipment, net | |
| 282,746 | |
| 238,266 |
Finance lease right-of-use assets | | | 564 | | | 753 |
Operating lease right-of-use assets | | | 32,333 | | | 25,554 |
Investment in unconsolidated affiliate | | | 527 | | | 2,414 |
Goodwill and intangible assets, net | |
| 613,295 | |
| 37,298 |
Long-term investments | | | 14,685 | | | — |
Other assets | |
| 25,910 | |
| 20,856 |
Deferred tax assets | |
| 53,252 | |
| 38,527 |
Total assets | | $ | 1,512,912 | | $ | 741,987 |
| | | | | | |
LIABILITIES AND STOCKHOLDERS' EQUITY | | | | | | |
Current liabilities: | | | | | | |
Accounts payable and accrued liabilities | | $ | 93,366 | | $ | 84,242 |
Accrued payments for BAQSIMI® | | | 126,090 | | | — |
Income taxes payable | |
| 1,609 | |
| 4,571 |
Current portion of long-term debt | |
| 436 | |
| 3,046 |
Current portion of operating lease liabilities | | | 3,906 | | | 3,003 |
Total current liabilities | |
| 225,407 | |
| 94,862 |
| | | | | | |
Long-term reserve for income tax liabilities | |
| 6,066 | |
| 7,225 |
Long-term debt, net of current portion and unamortized debt issuance costs | |
| 589,579 | |
| 72,839 |
Long-term operating lease liabilities, net of current portion | | | 29,721 | | | 23,694 |
Deferred tax liabilities | |
| — | |
| 144 |
Other long-term liabilities | |
| 22,718 | |
| 14,565 |
Total liabilities | |
| 873,491 | |
| 213,329 |
Commitments and contingencies | | | | | | |
Stockholders’ equity: | | | | | | |
Preferred stock: par value $0.0001; 20,000,000 shares authorized; no shares issued and outstanding | |
| — | |
| — |
Common stock: par value $0.0001; 300,000,000 shares authorized; 59,390,194 and 48,068,881 shares issued and outstanding as of December 31, 2023 and 58,110,231 and 48,112,069 shares issued and outstanding as of December 31, 2022, respectively | |
| 6 | |
| 6 |
Additional paid-in capital | |
| 486,056 | |
| 455,077 |
Retained earnings | |
| 409,268 | |
| 271,723 |
Accumulated other comprehensive loss | |
| (8,478) | |
| (8,624) |
Treasury stock | |
| (247,431) | |
| (189,524) |
Total equity | | | 639,421 | | | 528,658 |
Total liabilities and stockholders’ equity | | $ | 1,512,912 | | $ | 741,987 |
Table III
Amphastar Pharmaceuticals, Inc.
Reconciliation of Non-GAAP Measures
(Unaudited; in thousands, except per share data)
| | Three Months Ended | | Year Ended | ||||||||
| | December 31, | | December 31, | ||||||||
|
| 2023 |
| 2022 |
| 2023 |
| 2022 | ||||
| | | | | | | | | | | | |
GAAP net income |
| $ | 36,167 |
| $ | 33,913 |
| $ | 137,545 |
| $ | 91,386 |
Adjusted for: | | | | | | | | | | | | |
Intangible amortization | |
| 6,178 | |
| 331 | |
| 12,830 | |
| 1,419 |
Share-based compensation | |
| 4,622 | |
| 4,304 | |
| 20,242 | |
| 17,860 |
Impairment of long-lived assets | |
| 1 | |
| — | |
| 3,175 | |
| — |
Expenses related to BAQSIMI® acquisition | | | 2,148 | | | — | | | 5,830 | | | — |
Debt issuance costs | | | 742 | | | — | | | 6,785 | | | — |
Litigation settlements | | | — | | | — | | | — | | | (4,929) |
Income tax provision on pre-tax adjustments | |
| (2,983) | |
| (910) | |
| (10,708) | |
| (2,550) |
Non-GAAP net income | | $ | 46,875 | | $ | 37,638 | | $ | 175,699 | | $ | 103,186 |
| | | | | | | | | | | | |
Non-GAAP net income per share: | | | | | | | | | | | | |
Basic | | $ | 0.98 | | $ | 0.78 | | $ | 3.64 | | $ | 2.13 |
Diluted | | $ | 0.88 | | $ | 0.73 | | $ | 3.32 | | $ | 1.97 |
| | | | | | | | | | | | |
Weighted-average shares used to compute non-GAAP net income per share: | | | | | | | | | | | | |
Basic | |
| 47,957 | |
| 48,298 | |
| 48,265 | |
| 48,551 |
Diluted | |
| 53,014 | |
| 51,716 | |
| 53,001 | |
| 52,427 |
| | Three Months Ended December 31, 2023 | ||||||||||||||||
| | | | | | | | | | | | | | |||||
| | | | Selling, | | General | | Research | | Non-operating | | | ||||||
| | Cost of | | distribution | | and | | and | | (expenses) | | Income | ||||||
|
| revenue |
| and marketing |
| administrative |
| development |
| income, net |
| tax provision | ||||||
GAAP | | $ | 81,965 | | $ | 8,619 | | $ | 13,122 | | $ | 20,419 | | $ | (12,635) | | $ | 4,673 |
Intangible amortization | | | (6,158) | | | — | | | (3) | | | (17) | | | — | | | — |
Share-based compensation | | | (1,023) | | | (221) | | | (2,946) | | | (432) | | | — | | | — |
Impairment of long-lived assets | | | — | | | — | | | (1) | | | — | | | — | | | — |
Expenses related to BAQSIMI® acquisition | | | — | | | — | | | (322) | | | — | | | 1,826 | | | — |
Debt issuance costs | | | — | | | — | | | — | | | — | | | 742 | | | — |
Income tax provision on pre-tax adjustments | | | — | | | — | | | — | | | — | | | — | | | 2,983 |
Non-GAAP | | $ | 74,784 | | $ | 8,398 | | $ | 9,850 | | $ | 19,970 | | $ | (10,067) | | $ | 7,656 |
| | Three Months Ended December 31, 2022 | ||||||||||||||||
| | | | | | | | | | | | | | |||||
| | | | Selling, | | General | | Research | | Non-operating | | | ||||||
| | Cost of | | distribution | | and | | and | | (expenses) | | Income | ||||||
|
| revenue |
| and marketing |
| administrative |
| development |
| income, net |
| tax provision | ||||||
GAAP | | $ | 63,855 | | $ | 5,472 | | $ | 10,628 | | $ | 17,236 | | $ | 3,428 | | $ | 7,290 |
Intangible amortization | | | (205) | | | — | | | (126) | | | — | | | — | | | — |
Share-based compensation | | | (941) | | | (186) | | | (2,791) | | | (386) | | | — | | | — |
Income tax provision on pre-tax adjustments | | | — | | | — | | | — | | | — | | | — | | | 910 |
Non-GAAP | | $ | 62,709 | | $ | 5,286 | | $ | 7,711 | | $ | 16,850 | | $ | 3,428 | | $ | 8,200 |
| | Year Ended December 31, 2023 | ||||||||||||||||
| | | | | | | | | | | | | | |||||
| | | | Selling, | | General | | Research | | Non-operating | | | ||||||
| | Cost of | | distribution | | and | | and | | (expenses) | | Income | ||||||
|
| revenue |
| and marketing |
| administrative |
| development |
| income, net |
| tax provision | ||||||
GAAP | | $ | 293,274 | | $ | 28,853 | | $ | 51,540 | | $ | 73,741 | | $ | (25,628) | | $ | 31,833 |
Intangible amortization | | | (12,741) | | | — | | | (19) | | | (70) | | | — | | | — |
Share-based compensation | | | (4,891) | | | (870) | | | (12,269) | | | (2,212) | | | — | | | — |
Impairment of long-lived assets | | | (3,170) | | | — | | | (5) | | | — | | | — | | | — |
Expenses related to BAQSIMI® acquisition | | | — | | | — | | | (2,179) | | | — | | | 3,651 | | | — |
Debt issuance costs | | | — | | | — | | | — | | | — | | | 6,785 | | | — |
Income tax provision on pre-tax adjustments | | | — | | | — | | | — | | | — | | | — | | | 10,708 |
Non-GAAP | | $ | 272,472 | | $ | 27,983 | | $ | 37,068 | | $ | 71,459 | | $ | (15,192) | | $ | 42,541 |
| | Year Ended December 31, 2022 | ||||||||||||||||
| | | | | | | | | | | | | | |||||
| | | | Selling, | | General | | Research | | Non-operating | | | ||||||
| | Cost of | | distribution | | and | | and | | (expenses) | | Income | ||||||
|
| revenue |
| and marketing |
| administrative |
| development |
| income, net |
| tax provision | ||||||
GAAP | | $ | 250,127 | | $ | 21,531 | | $ | 45,061 | | $ | 74,771 | | $ | 8,543 | | $ | 23,477 |
Intangible amortization | | | (865) | | | — | | | (554) | | | — | | | — | | | — |
Share-based compensation | | | (4,179) | | | (726) | | | (11,180) | | | (1,775) | | | — | | | — |
Litigation settlements | | | — | | | — | | | (800) | | | — | | | (5,729) | | | — |
Income tax provision on pre-tax adjustments | | | — | | | — | | | — | | | — | | | — | | | 2,550 |
Non-GAAP | | $ | 245,083 | | $ | 20,805 | | $ | 32,527 | | $ | 72,996 | | $ | 2,814 | | $ | 26,027 |